{"product_id":"anti-human-vegfr2-kdr-flk-1-reference-antibody-vulinacimab-bha21415662","title":"Anti-Human VEGFR2\/KDR\/Flk-1 Reference Antibody (Vulinacimab)","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eReference Antibody\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cstrong\u003eVulinacimab\u003c\/strong\u003e (HW338056) is a research-grade recombinant antibody targeting CD309. Produced in mammalian cells with native-like glycosylation.\n\n\nHighlights\n\u003cul\u003e\n\u003cli\u003e●\u003cstrong\u003eResearch Grade\u003c\/strong\u003e — For PK\/PD studies, assay development, and ADA research.\u003c\/li\u003e\n\u003cli\u003e●\u003cstrong\u003eNative Glycosylation\u003c\/strong\u003e — Mammalian expression ensures native-like patterns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Species\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies Reactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1, kappa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eFLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eProtein A\/G purified from cell culture supernatant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% purity as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage Buffer\u003c\/th\u003e\n\u003ctd\u003e0.01M PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression System\u003c\/th\u003e\n\u003ctd\u003eMammalian Cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eUniProt\u003c\/th\u003e\n\u003ctd\u003eP35968\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\u003cth\u003eApplication\u003c\/th\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eELISA\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFlow Cytometry\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFunctional Assay\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIn Vivo Studies\u003c\/td\u003e\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eVascular endothelial growth factor receptor 2 (CD309\/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and\/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).\u003c\/p\u003e\n\u003ch2\u003eReactivity\u003c\/h2\u003e\n\u003cp\u003eThis antibody shows reactivity with Human.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003eFor Research Use Only (RUO). Not for use in diagnostic or therapeutic procedures.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Biohippo Inc","offers":[{"title":"1 mg","offer_id":53513339273581,"sku":"HW338056-1MG","price":352.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53513497215341,"sku":"HW338056-5MG","price":700.0,"currency_code":"USD","in_stock":true},{"title":"10 mg","offer_id":53513497248109,"sku":"HW338056-10MG","price":1000.0,"currency_code":"USD","in_stock":true},{"title":"25 mg","offer_id":53513497280877,"sku":"HW338056-25MG","price":1800.0,"currency_code":"USD","in_stock":true},{"title":"50 mg","offer_id":53513497313645,"sku":"HW338056-50MG","price":2800.0,"currency_code":"USD","in_stock":true},{"title":"100 mg","offer_id":53513497346413,"sku":"HW338056-100MG","price":4600.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/HW338056-SDS-PAGE-1.jpg?v=1783375325","url":"https:\/\/www.ebiohippo.com\/products\/anti-human-vegfr2-kdr-flk-1-reference-antibody-vulinacimab-bha21415662","provider":"BioHippo","version":"1.0","type":"link"}